Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The major capsid protein L1 from human papillomavirus type 6 is essential for virus assembly and infectivity. Its ability to form highly immunogenic virus-like particles has been harnessed successfully for preventive vaccines against multiple clinically relevant HPV types including those causing genital warts and cancers. Its structure-function relationship—especially its capacity to mimic native virions—makes it a cornerstone target molecule both biologically and therapeutically.
Induction of neutralizing antibodies through VLP presentation of L1 epitopes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Papillomavirus Type 6 Major Capsid Protein (L1) (None).